Literature DB >> 21363920

Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation.

Rosa Ana Risques1, Lisa A Lai, Cigdem Himmetoglu, Anoosheh Ebaee, Lin Li, Ziding Feng, Mary P Bronner, Bassel Al-Lahham, Kris V Kowdley, Keith D Lindor, Peter S Rabinovitch, Teresa A Brentnall.   

Abstract

Inflammation plays a role in the progression to cancer and it is linked to the presence of senescent cells. Ulcerative colitis (UC) is a chronic inflammatory disease that predisposes to colorectal cancer. Tumorigenesis in this setting is associated with telomere shortening that can be observed in the nondysplastic epithelium of UC patients with high-grade dysplasia (HGD) or cancer (UC progressors). We hypothesized that a preneoplastic field of inflammation, telomere shortening, and senescence underlies tumor progression in UC progressors. Multiple biopsies of varying histologic grade were collected along the colon of nine UC progressors and analyzed for telomere length, DNA damage, senescence, p53, p16, and chronic and acute inflammation. Twenty biopsies from four UC nonprogressors and twenty-one biopsies from control individuals without UC were also analyzed. Short telomeres and increased DNA damage, senescence, and infiltrating leukocytes were observed in biopsies located less than 10 cm from HGD or cancer. Low-grade dysplasia (LGD) had the shortest telomeres along with the highest levels of senescence and infiltrating leukocytes, whereas HGD biopsies showed the opposite pattern. The expression of p16 and p53 was low in nondysplastic biopsies but progressively increased in LGD and HGD. In addition, high levels of infiltrating leukocytes were associated with telomere shortening, senescence, and reduced p53 expression. These results suggest that dysplasia arises in a preneoplastic field of chronic inflammation, which leads to telomere shortening, DNA damage, and senescence. Our findings argue that senescence acts as a tumor suppressor mechanism that is abrogated during the transition from LGD to HGD in UC. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21363920      PMCID: PMC3077943          DOI: 10.1158/0008-5472.CAN-10-1966

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia.

Authors:  N A Wong; N J Mayer; S MacKell; H M Gilmour; D J Harrison
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

2.  High epithelial and stromal genetic instability of chromosome 17 in ulcerative colitis-associated carcinogenesis.

Authors:  Naoko Matsumoto; Tsutomu Yoshida; Isao Okayasu
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

3.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence.

Authors:  Yingjuan Qian; Jin Zhang; Bingfang Yan; Xinbin Chen
Journal:  J Biol Chem       Date:  2007-11-19       Impact factor: 5.157

5.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

6.  Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia.

Authors:  R F Willenbucher; D E Aust; C G Chang; S J Zelman; L D Ferrell; D H Moore; F M Waldman
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms.

Authors:  Jacintha N O'Sullivan; Jennifer C Finley; Rosa-ana Risques; Wen-Tang Shen; Katherine A Gollahon; Alexander H Moskovitz; Sergei Gryaznov; Calvin B Harley; Peter S Rabinovitch
Journal:  Cytometry A       Date:  2004-04       Impact factor: 4.355

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 9.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

10.  Leukocyte telomere length predicts cancer risk in Barrett's esophagus.

Authors:  Rosa Ana Risques; Thomas L Vaughan; Xiaohong Li; Robert D Odze; Patricia L Blount; Kamran Ayub; Jasmine L Gallaher; Brian J Reid; Peter S Rabinovitch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

View more
  67 in total

Review 1.  Cancer in inflammatory bowel disease: lessons from animal models.

Authors:  Daniel A Sussman; Rebeca Santaolalla; Sebastian Strobel; Rishu Dheer; Maria T Abreu
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

Review 2.  Precancer in ulcerative colitis: the role of the field effect and its clinical implications.

Authors:  Kathryn T Baker; Jesse J Salk; Teresa A Brentnall; Rosa Ana Risques
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

3.  Telomere length in non-neoplastic gastric mucosa and its relationship to H. pylori infection, degree of gastritis, and NSAID use.

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Tomohiko Kawamura; Takamitsu Ishizuka; Masaaki Okubo; Mitsuo Nagasaka; Yoshihito Nakagawa; Tomiyasu Arisawa; Naoki Ohmiya; Ichiro Hirata
Journal:  Clin Exp Med       Date:  2015-01-07       Impact factor: 3.984

Review 4.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

Review 5.  A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer.

Authors:  Ian S Reynolds; Aobhlinn O'Toole; Joseph Deasy; Deborah A McNamara; John P Burke
Journal:  Int J Colorectal Dis       Date:  2017-01-11       Impact factor: 2.571

6.  Pan-colonic field defects are detected by CGH in the colons of UC patients with dysplasia/cancer.

Authors:  Lisa A Lai; Rosa Ana Risques; Mary P Bronner; Peter S Rabinovitch; David Crispin; Ru Chen; Teresa A Brentnall
Journal:  Cancer Lett       Date:  2012-03-02       Impact factor: 8.679

7.  Neutrophil-derived microRNAs put the (DNA) breaks on intestinal mucosal healing.

Authors:  Eóin N McNamee
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

8.  Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancer.

Authors:  Ru Chen; Sheng Pan; Keith Lai; Lisa A Lai; David A Crispin; Mary P Bronner; Teresa A Brentnall
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis.

Authors:  Jesse J Salk; Aasthaa Bansal; Lisa A Lai; David A Crispin; Cigdem H Ussakli; Marshall S Horwitz; Mary P Bronner; Teresa A Brentnall; Lawrence A Loeb; Peter S Rabinovitch; Rosa Ana Risques
Journal:  Inflamm Bowel Dis       Date:  2013-11       Impact factor: 5.325

10.  Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors.

Authors:  Anitha K Shenoy; Robert C Fisher; Elizabeth A Butterworth; Liya Pi; Lung-Ji Chang; Henry D Appelman; Myron Chang; Edward W Scott; Emina H Huang
Journal:  Cancer Res       Date:  2012-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.